Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis
- Conditions
- Psoriasis
- Interventions
- Other: Acetylcholine iontophoresisOther: Sodium Nitroprussiate iontophoresisOther: ppi water iontophoresisOther: Laser Doppler recording
- Registration Number
- NCT02652065
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Psoriasis is a chronic inflammatory cutaneous disease, affecting 3% of the French population. Among psoriatic patients, 80% feel pain or cutaneous discomfort related to their pathology.
Neurogenic inflammation's role in psoriasis has recently been put forward by a study showing that TRPV1 ion channels are necessary to establish psoriasiform inflammation in mice.
The investigators hypothesize that there is a link between cutaneous sensory neuropathies and altered cutaneous microcirculation during psoriasis.
In order to test this hypothesis, local vasodilators will be delivered to patients by iontophoresis and their skin blood flow in response to these molecules will be followed by laser Doppler recordings. Two recordings will be performed for each patient, both on a psoriasis plaque and on uninvolved skin, in order for the patient to be his own internal control.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- Type I psoriasis
- Psoriasis plaques on the patient's back
- BMI > 25
- Diabetic patient
- Arteriovenous disease history
- Ongoing anti-inflammatory treatment
- Major cardiovascular history (<3 months)
- Hypertension
- Topical treatment on the back skin (<7 days)
- Systemic treatment (steroids, methotrexate, retinoids, cyclosporine) or phototherapy (<1 month)
- Pregnant women
- Subject within exclusion period following a previous or ongoing biomedical study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Healthy skin Acetylcholine iontophoresis Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on healthy skin. The skin blood flow in response to these molecules will be followed by laser Doppler recordings. Healthy skin ppi water iontophoresis Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on healthy skin. The skin blood flow in response to these molecules will be followed by laser Doppler recordings. Psoriasis plaque ppi water iontophoresis Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on a psoriasis plaque (on the patient's back). The skin blood flow in response to these molecules will be followed by laser Doppler recordings. Psoriasis plaque Sodium Nitroprussiate iontophoresis Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on a psoriasis plaque (on the patient's back). The skin blood flow in response to these molecules will be followed by laser Doppler recordings. Healthy skin Sodium Nitroprussiate iontophoresis Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on healthy skin. The skin blood flow in response to these molecules will be followed by laser Doppler recordings. Healthy skin Laser Doppler recording Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on healthy skin. The skin blood flow in response to these molecules will be followed by laser Doppler recordings. Psoriasis plaque Acetylcholine iontophoresis Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on a psoriasis plaque (on the patient's back). The skin blood flow in response to these molecules will be followed by laser Doppler recordings. Psoriasis plaque Laser Doppler recording Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on a psoriasis plaque (on the patient's back). The skin blood flow in response to these molecules will be followed by laser Doppler recordings.
- Primary Outcome Measures
Name Time Method skin blood flow variation at the latest 3 months after inclusion Skin blood flow variation on healthy skin and on psoriasis plaque will be measured by Laser Doppler in response to iontophoretic delivery of vasodilator substances (sodium nitroprussiate and acetylcholine) and ppi water. Skin blood flow will be recorded during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
- Secondary Outcome Measures
Name Time Method Sensory detection threshold at the latest 3 months after inclusion Increasing size of Von Frey filaments will be placed onto patients' skin to assess sensory detection threshold.
Potential discomfort sensation thresholds at the latest 3 months after inclusion Increasing size of Von Frey filaments will be placed onto patients' skin to assess potential discomfort sensation threshold.
Heat sensitivity at the latest 3 months after inclusion Heat sensitivity will be assessed using hot (50°C) and cold (4°C) water
Trial Locations
- Locations (1)
Hôpital Edouard Herriot - Service de Dermatologie et Vénéréologie
🇫🇷LYON cedex 03, France